This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kleiman, N. S. Search for Related Content PubMed PubMed Citation Articles by Kleiman, N. S.

Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non–ST-elevation acute coronary syndromes

Neal S. Kleiman, MD^*,*, Nasser Lakkis, MD^*, Christopher P. Cannon, MD, Sabina A. Murphy, MPH, Peter M. DiBattiste, MD, Laura A. Demopoulos, MD, William S. Weintraub, MD, Eugene Braunwald, MD TACTICS-TIMI 18 Investigators

^* Baylor College of Medicine and The Methodist-DeBakey Heart Center, Houston, Texas, USA
Brigham and Women’s Hospital, Boston, Massachusetts, USA
Merck Inc., West Point, Pennsylvania, USA
Emory University, Atlanta, Georgia, USA

View larger version (17K): [in a new window]   Figure 1 Kaplan-Meier estimates of survival free of the composite end point according to creatine kinase muscle-brain fraction (CK-MB) status and assignment to an invasive or conservative strategy.

View larger version (15K): [in a new window]   Figure 2 Kaplan-Meier estimates of survival free of death or myocardial infarction according to creatine kinase muscle-brain fraction (CK-MB) status and assignment to an invasive or conservative strategy.